Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Yang A, Dai J, Xie Z, Colman RW, Wu Q, Birge RB, Wu Y.

J Immunol. 2014 May 1;192(9):4398-408. doi: 10.4049/jimmunol.1302590. Epub 2014 Mar 31.

2.

Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).

Pixley RA, Espinola RG, Ghebrehiwet B, Joseph K, Kao A, Bdeir K, Cines DB, Colman RW.

Thromb Haemost. 2011 Jun;105(6):1053-9. doi: 10.1160/TH10-09-0591. Epub 2011 May 5.

3.

Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Larusch GA, Merkulova A, Mahdi F, Shariat-Madar Z, Sitrin RG, Cines DB, Schmaier AH.

Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H305-20. doi: 10.1152/ajpheart.00110.2013. Epub 2013 May 24.

4.

Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.

Chavakis T, Kanse SM, Lupu F, Hammes HP, Müller-Esterl W, Pixley RA, Colman RW, Preissner KT.

Blood. 2000 Jul 15;96(2):514-22.

5.

The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells.

D'mello V, Singh S, Wu Y, Birge RB.

J Biol Chem. 2009 Jun 19;284(25):17030-8. doi: 10.1074/jbc.M109.010066. Epub 2009 Apr 21.

6.

Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor.

Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH.

J Biol Chem. 2004 Apr 16;279(16):16621-8. Epub 2004 Feb 5.

7.

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis.

Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, Fazio S, Linton MF.

J Lipid Res. 2015 Aug;56(8):1449-60. doi: 10.1194/jlr.M056689. Epub 2015 Jun 9.

8.

Participation of the receptor for advanced glycation end products in efferocytosis.

Friggeri A, Banerjee S, Biswas S, de Freitas A, Liu G, Bierhaus A, Abraham E.

J Immunol. 2011 Jun 1;186(11):6191-8. doi: 10.4049/jimmunol.1004134. Epub 2011 Apr 18.

9.

Participation of the urokinase receptor in neutrophil efferocytosis.

Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E.

Blood. 2009 Jul 23;114(4):860-70. doi: 10.1182/blood-2008-12-193524. Epub 2009 Apr 27.

10.

Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages.

Bae HB, Tadie JM, Jiang S, Park DW, Bell CP, Thompson LC, Peterson CB, Thannickal VJ, Abraham E, Zmijewski JW.

J Immunol. 2013 Mar 1;190(5):2273-81. doi: 10.4049/jimmunol.1200625. Epub 2013 Jan 23.

11.

The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.

Liu Y, Cao DJ, Sainz IM, Guo YL, Colman RW.

Am J Physiol Cell Physiol. 2008 Jul;295(1):C257-67. doi: 10.1152/ajpcell.00569.2007. Epub 2008 May 21.

12.

Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR.

J Clin Invest. 1997 Sep 15;100(6):1481-7.

13.

Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.

Briassouli P, Komissarova EV, Clancy RM, Buyon JP.

Circ Res. 2010 Aug 6;107(3):374-87. doi: 10.1161/CIRCRESAHA.109.213629. Epub 2010 Jun 17.

14.

Co-receptors are dispensable for tethering receptor-mediated phagocytosis of apoptotic cells.

Park B, Lee J, Moon H, Lee G, Lee DH, Cho JH, Park D.

Cell Death Dis. 2015 May 28;6:e1772. doi: 10.1038/cddis.2015.140.

15.

The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Jo M, Takimoto S, Montel V, Gonias SL.

Am J Pathol. 2009 Jul;175(1):190-200. doi: 10.2353/ajpath.2009.081053. Epub 2009 Jun 4.

16.

Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells.

Mahdi F, Shariat-Madar Z, Todd RF 3rd, Figueroa CD, Schmaier AH.

Blood. 2001 Apr 15;97(8):2342-50.

17.

Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling.

Colman RW, Wu Y, Liu Y.

Thromb Haemost. 2010 Nov;104(5):875-85. doi: 10.1160/TH10-01-0017. Epub 2010 Sep 30. Review.

PMID:
20886177
18.

Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.

Liu Y, Pixley R, Fusaro M, Godoy G, Kim E, Bromberg ME, Colman RW.

Oncogene. 2009 Jul 30;28(30):2756-65. doi: 10.1038/onc.2009.132. Epub 2009 Jun 1.

19.

A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Liu D, Zhou D, Wang B, Knabe WE, Meroueh SO.

ACS Chem Biol. 2015 Jun 19;10(6):1521-34. doi: 10.1021/cb500832q. Epub 2015 Mar 31.

Supplemental Content

Support Center